EP1516049A4 - Zusammensetzungen und verfahren für die therapie und diagnose von lungenkrebs - Google Patents

Zusammensetzungen und verfahren für die therapie und diagnose von lungenkrebs

Info

Publication number
EP1516049A4
EP1516049A4 EP02739247A EP02739247A EP1516049A4 EP 1516049 A4 EP1516049 A4 EP 1516049A4 EP 02739247 A EP02739247 A EP 02739247A EP 02739247 A EP02739247 A EP 02739247A EP 1516049 A4 EP1516049 A4 EP 1516049A4
Authority
EP
European Patent Office
Prior art keywords
diagnosis
therapy
compositions
methods
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02739247A
Other languages
English (en)
French (fr)
Other versions
EP1516049A2 (de
Inventor
Michael J Lodes
Tongtong Wang
Liqun Fan
Paul A Algate
Patricia D Mcneill
Robert A Henderson
Raodoh Moahamath
Heather Secrist
Darin R Benson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/854,133 external-priority patent/US6759508B2/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of EP1516049A2 publication Critical patent/EP1516049A2/de
Publication of EP1516049A4 publication Critical patent/EP1516049A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP02739247A 2001-05-11 2002-05-10 Zusammensetzungen und verfahren für die therapie und diagnose von lungenkrebs Withdrawn EP1516049A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/854,133 US6759508B2 (en) 2000-09-01 2001-05-11 Compositions and methods for the therapy and diagnosis of lung cancer
US854133 2001-05-11
PCT/US2002/014975 WO2002092001A2 (en) 2001-05-11 2002-05-10 Compositions and methods for the therapy and diagnosis of lung cancer

Publications (2)

Publication Number Publication Date
EP1516049A2 EP1516049A2 (de) 2005-03-23
EP1516049A4 true EP1516049A4 (de) 2006-01-11

Family

ID=25317820

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02739247A Withdrawn EP1516049A4 (de) 2001-05-11 2002-05-10 Zusammensetzungen und verfahren für die therapie und diagnose von lungenkrebs

Country Status (3)

Country Link
EP (1) EP1516049A4 (de)
AU (1) AU2002311909A1 (de)
WO (1) WO2002092001A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US7226791B2 (en) * 2003-06-02 2007-06-05 Bristol-Myers Squibb Company Polynucleotides encoding novel guanylate binding proteins (GBP's)
DK2733492T3 (en) 2008-08-05 2016-04-25 Toray Industries Method for detection of cancer
CN102170907A (zh) 2008-08-05 2011-08-31 东丽株式会社 用于治疗和预防癌症的药物组合物
BR112012018948B1 (pt) 2010-02-04 2021-12-14 Toray Industries, Inc Composições farmacêuticas, anticorpos, combinação farmacêutica, usos de uma composição farmacêutica, uso de um anticorpo e uso de uma combinação farmacêutica
PT2532367T (pt) 2010-02-04 2018-11-09 Toray Industries Agente farmacêutico para o tratamento e/ou prevenção do cancro
US9115200B2 (en) 2010-02-04 2015-08-25 Toray Industries, Inc. Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1
CA2788716C (en) 2010-02-04 2019-06-18 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
MX340015B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CA2788547C (en) 2010-02-04 2018-06-05 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
PL2740796T3 (pl) 2011-08-04 2017-10-31 Toray Industries Kompozycja farmaceutyczna do leczenia nowotworu i/lub zapobiegania nowotworowi
PT2740798T (pt) 2011-08-04 2017-03-13 Toray Industries Composição de fármaco para o tratamento e/ou a prevenção de cancro
KR101968498B1 (ko) 2011-08-04 2019-04-12 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
PT2740489T (pt) 2011-08-04 2017-01-10 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
JP6065590B2 (ja) 2011-08-04 2017-01-25 東レ株式会社 癌の治療及び／又は予防用医薬組成物
PL2740795T3 (pl) 2011-08-04 2017-04-28 Toray Industries, Inc. Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi
CA2844033C (en) 2011-08-04 2021-07-27 Toray Industries, Inc. Method for detecting pancreatic cancer
IN2014KN01716A (de) 2012-02-21 2015-10-23 Toray Industries
BR112014021099A2 (pt) 2012-02-21 2020-12-01 Toray Industries, Inc anticorpo, composição farmacêutica, dna e método de tratamento e/ou prevenção de câncer e uso de um anticorpo
DK2818483T3 (en) 2012-02-21 2017-10-23 Toray Industries Medical composition for the treatment and / or prevention of cancer
US9273130B2 (en) 2012-02-21 2016-03-01 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
US9428581B2 (en) 2012-03-30 2016-08-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
PT2832365T (pt) 2012-03-30 2018-01-24 Toray Industries Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático
WO2014014086A1 (ja) 2012-07-19 2014-01-23 東レ株式会社 癌の検出方法
RU2646466C2 (ru) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Метод детекции рака
JP6447130B2 (ja) 2013-08-09 2019-01-09 東レ株式会社 癌の治療及び／又は予防用医薬組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000828A2 (en) * 1999-06-30 2001-01-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001072295A2 (en) * 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001096390A2 (en) * 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834248A (en) * 1995-02-10 1998-11-10 Millennium Pharmaceuticals Inc. Compositions and methods using rchd534, a gene uregulated by shear stress

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000828A2 (en) * 1999-06-30 2001-01-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001072295A2 (en) * 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001096390A2 (en) * 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 2 May 2001 (2001-05-02), "Homo sapiens cystine/glutamate transporter xCT mRNA", XP002337270, retrieved from EBI Database accession no. AF252872 *
DATABASE EMBL 5 August 1999 (1999-08-05), "Seq ID no: 3414", XP002337271, retrieved from EBI Database accession no. AAZ15945 *
DATABASE EMBL XP002337272, retrieved from EBI Database accession no. AAZ12811 *

Also Published As

Publication number Publication date
WO2002092001A2 (en) 2002-11-21
WO2002092001A3 (en) 2005-01-13
AU2002311909A1 (en) 2002-11-25
EP1516049A2 (de) 2005-03-23

Similar Documents

Publication Publication Date Title
PL366626A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
PL354093A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
EP1516049A4 (de) Zusammensetzungen und verfahren für die therapie und diagnose von lungenkrebs
EP1515982A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von prostatakrebs
AU2002251841A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2002218770A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2003302892A8 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2002251844A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
EP1571968A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
EP1572091A4 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
PL365244A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
EP1553912A4 (de) Zusammensetzungen und verfahren f r die tumordiagnose und behandlung
AU2002254482A1 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
EP1575571A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung eines tumors
EP1446013A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
AU2002246519A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
AU2001259062A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
EP1420814A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von brustkrebs
EP1349485A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose des ovarialkarzinoms
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
PL366066A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU2003230849A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031211

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1075674

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20051123

17Q First examination report despatched

Effective date: 20061110

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090122

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1075674

Country of ref document: HK